Citius Pharmaceuticals (Nasdaq:CTXR) - Aandelenkoers, Nieuws & Analyse

CTXR Overzicht aandelen

Citius Pharmaceuticals, Inc. is een biofarmaceutisch bedrijf dat zich richt op de ontwikkeling en commercialisering van producten voor kritieke zorg.

Over het bedrijf

CTXR fundamentele analyse
Sneeuwvlok Score
Waardering	4/6
Toekomstige groei	5/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Verhandeld tegen 95.5% onder onze schatting van de reële waarde

De winst zal naar verwachting met 49.91% per jaar groeien

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Aandeelhouders zijn het afgelopen jaar verwaterd

Heeft geen betekenisvolle marktkapitalisatie ( $63M )

Volatiele aandelenkoers in de afgelopen 3 maanden

Citius Pharmaceuticals, Inc. Concurrenten

Zynerba Pharmaceuticals

NasdaqCM:ZYNE

US$65.6m

Nutriband

NasdaqCM:NTRB

US$62.7m

MariMed

OTCPK:MRMD

US$57.3m

Landos Biopharma

NasdaqCM:LABP

US$71.7m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Citius Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	US$0.38
52 Week Hoogtepunt	US$1.07
52 Week Laag	US$0.31
Bèta	1.61
11 maand verandering	-1.60%
3 maanden verandering	-51.00%
1 Jaar Verandering	-50.36%
33 jaar verandering	-79.00%
5 jaar verandering	-23.56%
Verandering sinds IPO	-97.45%

Recent nieuws en updates

Recent updates

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully

Apr 06

We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate

Dec 08

Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?

Aug 01

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Apr 12

Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation

Dec 25

Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK

Sep 28

Citius Pharmaceuticals GAAP EPS of -$0.06

Aug 11

Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely

Aug 05

Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK

Jul 12

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Dec 04

Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization

Sep 26

Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth

Aug 28

Citius: Halt For Superiority On The Horizon

Jun 15

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

May 15

Citius Pharmaceuticals shares rise in anticipation of Mino-Lok phase 3 results

Apr 26

Is Citius Pharmaceuticals (NASDAQ:CTXR) In A Good Position To Deliver On Growth Plans?

Dec 18

Rendement voor aandeelhouders

	CTXR	US Pharmaceuticals	US Markt
7D	2.5%	-2.2%	5.1%
1Y	-50.4%	15.6%	37.7%

Rendement versus industrie: CTXR presteerde slechter dan de US Pharmaceuticals -sector, die het afgelopen jaar een rendement van 15.6 % opleverde.

Rendement versus markt: CTXR presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 37.7 % opleverde.

Prijsvolatiliteit

Is CTXR's price volatile compared to industry and market?
CTXR volatility
CTXR Average Weekly Movement	11.5%
Pharmaceuticals Industry Average Movement	9.6%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.1%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: De aandelenkoers van CTXR is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 12% ) van CTXR is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2007	22	Leonard Mazur	citiuspharma.com

Citius Pharmaceuticals, Inc. is een biofarmaceutisch bedrijf dat zich toelegt op de ontwikkeling en commercialisering van producten voor kritieke zorg. LYMPHIR, een door de FDA goedgekeurd product, is een doelgerichte immuuntherapie voor een eerste indicatie in de behandeling van cutaan T-cel lymfoom. De pijplijn in een laat stadium omvat Mino-Lok, een antibiotische lock-oplossing om katheters te redden bij patiënten met katheter-gerelateerde bloedstroominfecties; en CITI-002 (Halo-Lido), een topische formulering voor de verlichting van aambeien.

Citius Pharmaceuticals, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Citius Pharmaceuticals zich tot de beurswaarde?
CTXR fundamentele statistieken
Marktkapitalisatie	US$62.71m
Inkomsten(TTM)	-US$39.77m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-1.7x

Koers/Winstverhouding

Is CTXR overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
CTXR resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$39.77m
Inkomsten	-US$39.77m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.22
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde CTXR op de lange termijn?

Bekijk historische prestaties en vergelijking

CTXR Overzicht aandelen

Beloningen

Risicoanalyse

Citius Pharmaceuticals, Inc. Concurrenten

NasdaqCM:ZYNE

US$65.6m

NasdaqCM:NTRB

US$62.7m

OTCPK:MRMD

US$57.3m

NasdaqCM:LABP

US$71.7m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Citius Pharmaceuticals, Inc. Provides Non-Compliance Update

New minor risk - Market cap size

Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Citius Pharmaceuticals, Inc. Receives FDA Approval for LYMPHIR Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Price target increased by 22% to US$4.67

Forecast breakeven date pushed back to 2026

Recent updates

Citius Pharmaceuticals, Inc. Provides Non-Compliance Update

New minor risk - Market cap size

Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Citius Pharmaceuticals, Inc. Receives FDA Approval for LYMPHIR Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Price target increased by 22% to US$4.67

Forecast breakeven date pushed back to 2026

Citius Pharmaceuticals, Inc. Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $15.000002 million.

Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully

New minor risk - Share price stability

The Nasdaq Stock Market LLC Grants Citius Pharmaceuticals' Request for an Extension through September 9, 2024 to Evidence Compliance with the Bid Price Rule Pursuant to Nasdaq Listing Rule 5550(a)(2)

Forecast breakeven date pushed back to 2026

Citius Pharmaceuticals, Inc. Announces the Resubmission of the Biologics License Application to the U.S. Food and Drug Administration for Lymphir

New minor risk - Market cap size

Citius Pharmaceuticals, Inc., Annual General Meeting, Mar 12, 2024

Citius Pharmaceuticals, Inc. Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok Therapeutic to Salvage Catheters

New major risk - Financial position

New minor risk - Profitability

We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate

Citius Pharmaceuticals, Inc. Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor

New minor risk - Share price stability

Citius Pharmaceuticals, Inc. Announces Changes to its Audit Committee

Citius Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Stock Market

Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration Regarding the Planned Resubmission of the BLA for LYMPHIR

Citius Pharmaceuticals, Inc. Reaches 92 Event Milestone in Mino-Lok Phase 3 Trial

Price target decreased by 21% to US$3.17

Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?

Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Citius Pharmaceuticals, Inc. Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids

Consensus EPS estimates fall by 24%

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Forecast breakeven date pushed back to 2025

Price target increased by 25% to US$5.00

Forecast breakeven date pushed back to 2025

Citius Pharmaceuticals, Inc. Appoints Dennis M. McGrath to Board of Directors

Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation

Citius Pharmaceuticals, Inc., Annual General Meeting, Feb 07, 2023

Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

Price target decreased to US$3.60

Insufficient new directors

Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK

Citius Pharmaceuticals GAAP EPS of -$0.06

Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely

Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma

Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK

Citius Pharmaceuticals: Hoping For A Turnaround Strategy

Price target increased to US$4.00

Insufficient new directors

Citius Pharmaceuticals, Inc. Enrolls First Patient in Phase 2B Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

Citius Pharmaceuticals, Inc. Announces Executive Changes

Critical Care Biopharma - Citius Pharmaceuticals

Forecast breakeven date pushed back to 2024

Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/Ontak (E7777)

Citius: 2022 Is A Year Of Catalysts

Citius Pharmaceuticals Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

Forecast breakeven date moved forward to 2023

Citius Pharmaceuticals, Inc. Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma